Opus Genetics, Inc. (IRD)
| Market Cap | 40.92M |
| Revenue (ttm) | 10.99M |
| Net Income (ttm) | -57.53M |
| Shares Out | 44.96M |
| EPS (ttm) | -2.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 224,688 |
| Open | 0.9860 |
| Previous Close | 0.9818 |
| Day's Range | 0.8860 - 1.0000 |
| 52-Week Range | 0.8100 - 2.3400 |
| Beta | 0.27 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+779.12%) |
| Earnings Date | May 15, 2025 |
About IRD
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II cl... [Read more]
Financial Performance
In 2024, Opus Genetics's revenue was $10.99 million, a decrease of -42.30% compared to the previous year's $19.05 million. Losses were -$57.53 million, 476.1% more than in 2023.
Financial numbers in USD Financial StatementsAnalyst Forecast
According to one analyst, the rating for IRD stock is "Strong Buy" and the 12-month stock price forecast is $8.0.
News
Opus Genetics Announces Financial Results for Full Year 2024
Provides update on the Company's transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases
Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics
Believes that Current Board's Strategic, Management and Capital Allocation Failures have Resulted in Stockholder Value Destruction
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX
RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inh...
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
Additional approximately $21 million tied to data release for the Company's BEST1 program Additional approximately $21 million tied to data release for the Company's BEST1 program
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., March 19, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the tre...
Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
New Data from First Three Adult Patients in Phase 1/2 Trial with OPGx-LCA5 Showed that Subjective and Objective Signs of Efficacy Persisted for One Year New Data from First Three Adult Patients in Pha...
Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs
FDA Fast Track Designation granted for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night driving impairment in keratorefractive patients with reduced mesopic vision Enro...
Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025 New 12-month data on the first three adult OPGx-LCA5 patients to be p...
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.
Current Board's Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 Months
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opus Gene...